0001179110-17-014597.txt : 20171124
0001179110-17-014597.hdr.sgml : 20171124
20171124175442
ACCESSION NUMBER: 0001179110-17-014597
CONFORMED SUBMISSION TYPE: 4/A
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20171121
FILED AS OF DATE: 20171124
DATE AS OF CHANGE: 20171124
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Dorsch Marion
CENTRAL INDEX KEY: 0001690460
FILING VALUES:
FORM TYPE: 4/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37359
FILM NUMBER: 171221733
MAIL ADDRESS:
STREET 1: BLUEPRINT MEDICINES CORPORATION
STREET 2: 38 SIDNEY STREET, SUITE 200
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Blueprint Medicines Corp
CENTRAL INDEX KEY: 0001597264
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 38 SIDNEY STREET, SUITE 200
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617-374-7580
MAIL ADDRESS:
STREET 1: 38 SIDNEY STREET, SUITE 200
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4/A
1
edgar.xml
FORM 4/A -
X0306
4/A
2017-11-21
2017-11-22
0
0001597264
Blueprint Medicines Corp
BPMC
0001690460
Dorsch Marion
C/O BLUEPRINT MEDICINES CORPORATION
38 SIDNEY STREET, SUITE 200
CAMBRIDGE
MA
02139
0
1
0
0
Chief Scientific Officer
Common Stock
2017-11-21
4
S
0
500
64.44
D
0
D
The sales reported on this Form 4/A were effected pursuant to a trading plan adopted on June 22, 2017 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
This amendment is being filed solely to correct the fact that the original filing inadvertently stated that these securities were acquired, rather than disposed of.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.42 to $64.51 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges.
/s/ Christopher Frankenfield, Attorney-in-Fact
2017-11-24